Canadian Cancer Trials Group Bulletins

Trial Management Group


Canadian Cancer Trials Group MA.32 Trial Accrual

The Canadian Cancer Trials Group MA.32 team is pleased to announce that international collaborations with the United Kingdom through its Institute of Cancer Research - Clinical Trials and Statistics Unit (ICR-CTSU) and with centres in Switzerland through the International Breast Cancer Study Group (IBCSG) have led to patient accruals to the MA.32 trial.

The North Bristol NHS Trust enrolled the first UK patient on September 11, 2012 and the Universitätsklinik für medizinische Onkologie Inselspital in Switzerland enrolled the first IBCSG patient on September 14, 2012.

We thank our ICR-CTSU and IBCSG collaborators for their participation and are very grateful for the stellar leadership Dr. Pamela Goodwin has provided as the Study Chair of MA.32.

Overall, accrual is proceeding well towards the target of 3582 patients with 2716 patients enrolled to date and 57 so far in September.

Thank you to all our participating sites for your support of this important clinical trial.